MSB 5.11% $1.67 mesoblast limited

Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-2

  1. 611 Posts.
    lightbulb Created with Sketch. 18
    Data Monitoring Committee (DMC) has performed another, scheduled review of the CHF trial data and recommended continuation of the trial without modification. Enrollment of this Phase 3 trial is expected to be completed by the end of 2018.

    LVAD National Institutes for Health (NIH) Phase 2 trial has also completed enrollment with 12-month data read-out expected in the next quarter (Q3 CY18). Mesoblast is actively pursuing a potential accelerated entry pathway for MPC-150-IM into the cardiovascular market that may be provided by RMAT designation.

    So, my take on this is both of these Tier 1 trials are confirmed on track with results coming in expected time-frames.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.67
Change
-0.090(5.11%)
Mkt cap ! $293.1M
Open High Low Value Volume
$1.88 $1.88 $1.57 $27.52M 16.47M

Buyers (Bids)

No. Vol. Price($)
1 6525 $1.66
 

Sellers (Offers)

Price($) Vol. No.
$1.67 18768 1
View Market Depth
Last trade - 16.10pm 05/12/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.